-
Amgen NASDAQ:AMGN Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Location: 1 Amgen Center Dr, California, 91320-1799, US | Website: www.amgen.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
200.9B
Cash
9.011B
Avg Qtr Burn
N/A
Short % of Float
1.83%
Insider Ownership
0.25%
Institutional Own.
81.04%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
KRYSTEXXA Details Chronic refractory gout | Approved Quarterly sales | |
Uplizna® (inebilizumab-cdon) Details Inflammatory disease | Approved Quarterly sales | |
TAVNEOS (Avacopan) (C5aR) Details ANCA-Associated Vasculitis, Autoimmune disease | Approved Quarterly sales | |
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
TEPEZZA Details Thyroid Eye Disease , Eye disease | Approved Quarterly sales | |
IMDELLTRA (Tarlatamab) (AMG 757) Details Lung cancer, Cancer, Small cell lung cancer | Approved Quarterly sales | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details IgG4-related disease | BLA Submission | |
BLINCYTO® (blinatumomab) + Low intensity chemo Details B-cell acute lymphoblastic leukemia | Phase 3 Data readout | |
Olpasiran (AMG 890) Details Atherosclerotic cardiovascular disease | Phase 3 Data readout | |
Bemarituzumab Details Gastric cancer | Phase 3 Data readout | |
TEZSPIRE Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Nplate® Details Chemo-induced thrombocytopenia | Phase 3 Data readout | |
Rocatinlimab Details Atopic dermatitis | Phase 3 Data readout | |
LUMAKRAS/LUMYKRAS (sotorasib) Details Non-small cell lung carcinoma | Phase 3 Data readout | |
TAVNEOS (Avacopan) (C5aR) Details Skin disease/disorder, Hidradenitis suppurativa | Phase 3 Update | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Neuromuscular disease, Myasthenia gravis | Phase 3 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Autoimmune disease, Cellulite | Phase 3 Initiation | |
Phase 3 Initiation | ||
Fipaxalparant (AMG 670) (HZN-825) Details Idiopathic pulmonary fibrosis | Phase 2b Data readout | |
Bempikibart (ADX-914) Details Atopic dermatitis | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Dazodalibep (HZN-4920) Details Kidney disease, Lupus nephritis, Autoimmune disease | Phase 2 Data readout | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Cutaneous lupus erythematosus | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Alopecia areata | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Systemic lupus erythematosus | Phase 2 Update | |
TAVNEOS (Avacopan) (C5aR) Details Kidney disease, C3 Glomerulopathy | Phase 2 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis | Phase 2 Update | |
Tezspire Details Chronic obstructive pulmonary disease | Phase 2a Update | |
LUMAKRAS + Vectibix and FOLFIRI Details Cancer, Colorectal cancer | Phase 1b Data readout | |
IMDELLTRA (Tarlatamab) (AMG 757) + PD-L1 inhibitor Details Small cell lung cancer, Lung cancer, Cancer | Phase 1b Update | |
HZN-457 Details Chronic refractory gout | Phase 1 Data readout | |
AMG 193 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Xaluritamig Details Cancer, Castration-resistant prostate cancer | Phase 1 Data readout | |
AMG 786 Details Obesity | Phase 1 Update |